It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Compare the flexibility of zero based budgeting with traditional budgets to understand tradeoffs and where each works best.
21,079 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Biotech shares retreat as Moderna slides 11% and ImmunityBio falls, with Sarepta also sinking amid a broad market rot...
Buffett's latest caution mirrors his Dot-Com-era warnings. In a market buzzing with hype, where does prudence fit in?...
Chip stocks slipped as SK Hynix flagged weaker memory demand and a jump in oil prices threatened chip margins. The tr...
The real risk retirement isn’t just running out of money; it’s waning purchasing power over time. This report explore...
From a tiny boat-insurer niche to a public company, Hagerty’s story is a case study in branding, community, and strat...
Amazon’s hidden silicon engine is lifting cloud profits, with Trainium, Graviton, and Nitro driving a new growth wave...
Energy markets pivot as renewables rise and fossil fuels adapt; several penny stocks are drawing attention for their ...
Investors can gain exposure to Bill Ackman’s top stocks without buying Pershing Square. A trio of ETFs offers a cost-...
AST SpaceMobile faced a sharp weekly drop after announcing a large convertible debt raise. This article explains why ...
A popular fallen angel ETF delivers about 6% yield paid monthly by buying bonds downgraded from investment grade. It’...
New York City unveils a plan to force disclosure of AI-edited rental photos, part of a broader tenant-protection pack...